Months after bursting into the bispecific scene out of nowhere, Janux follows the Merck hype to an IPO

Hot off of a $1 billion deal with Merck signed in December, Janux Therapeutics has been on a tear with virtually back-to-back financing rounds. Now, it’s ready for Wall Street.

Janux filed an IPO with the SEC Wednesday with a $100 million proposed offering, though that number has become...

Click to view original post